Literature DB >> 2557897

Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II.

F H Drake1, G A Hofmann, H F Bartus, M R Mattern, S T Crooke, C K Mirabelli.   

Abstract

The p170 and p180 forms of topoisomerase II have been compared. The concentration dependence of ATP for catalytic activity of the two forms of the enzyme was identical, and each was equally sensitive to novobiocin. Orthovanadate was found to be a potent inhibitor of catalytic activity of both p170 and p180, with an IC50 value of about 2 microM for each. Under standard reaction conditions, relaxation of supercoiled pBR322 by p180 was highly processive, while p170 performed the same reaction in a distributive manner. The optimal concentration of KCl for catalytic activity of p180 was 20-30 mM higher than that for p170. Comparison of their thermal stability showed that p180 was inactivated at twice the rate of p170. Teniposide and merbarone selectively inhibited catalytic activity of p170, requiring concentrations 3-fold and 8-fold lower, respectively, than those required for equivalent inhibition of p180. Similar selectivity for p170 was seen for teniposide-stimulated DNA cleavage or its inhibition by merbarone. Analysis of sites of DNA cleavage indicated a subset of sites that were either preferred or unique for each of the enzymes. A synthetic oligonucleotide representative of p170 sites selectively inhibited the p170 enzyme. Immunoblotting of p170 and p180 from U937 cells at different stages of proliferation showed that p170 levels declined as the cells reached the plateau phase of growth, while p180 levels were low during rapid proliferation and increased as the growth rate slowed. The data indicate that the p170 and p180 forms of topoisomerase II can be distinguished biochemically, pharmacologically, and by differential cellular regulation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2557897     DOI: 10.1021/bi00446a029

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  103 in total

1.  Topoisomerase II-mediated alterations of K562 drug resistant sublines.

Authors:  R Zhou; Y Wang; A Gruber; R Larsson; E Castaños-Vèlez; E Liliemark
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

2.  Sp1 mediates cell proliferation-dependent regulation of rat DNA topoisomerase IIalpha gene promoter.

Authors:  J H Yoon; J K Kim; G B Rha; M Oh; S H Park; R H Seong; S H Hong; S D Park
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

3.  Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35.

Authors:  B Grigolo; I Mazzetti; R Meliconi; S Bazzi; R Scorza; M Candela; A Gabrielli; A Facchini
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

4.  The topoisomerase IIbeta circular clamp arrests transcription and signals a 26S proteasome pathway.

Authors:  Hai Xiao; Yong Mao; Shyamal D Desai; Nai Zhou; Chun-Yuan Ting; Jaulang Hwang; Leroy F Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

5.  Cellular distribution of mammalian DNA topoisomerase II is determined by its catalytically dispensable C-terminal domain.

Authors:  N Adachi; M Miyaike; S Kato; R Kanamaru; H Koyama; A Kikuchi
Journal:  Nucleic Acids Res       Date:  1997-08-01       Impact factor: 16.971

Review 6.  The function of DNA topoisomerase IIβ in neuronal development.

Authors:  Xin Heng; Wei-Dong Le
Journal:  Neurosci Bull       Date:  2010-10       Impact factor: 5.203

7.  Impact of the C-terminal domain of topoisomerase IIalpha on the DNA cleavage activity of the human enzyme.

Authors:  Jennifer S Dickey; Neil Osheroff
Journal:  Biochemistry       Date:  2005-08-30       Impact factor: 3.162

8.  The geometry of DNA supercoils modulates topoisomerase-mediated DNA cleavage and enzyme response to anticancer drugs.

Authors:  A Kathleen McClendon; Neil Osheroff
Journal:  Biochemistry       Date:  2006-03-07       Impact factor: 3.162

9.  Tyrosine 656 in topoisomerase IIβ is important for the catalytic activity of the enzyme: Identification based on artifactual +80-Da modification at this site.

Authors:  Adrian G Grozav; Belinda B Willard; Toshiyuki Kozuki; Kenichi Chikamori; Marius A Micluta; Andrei-Jose Petrescu; Michael Kinter; Ram Ganapathi; Mahrukh K Ganapathi
Journal:  Proteomics       Date:  2011-01-31       Impact factor: 3.984

Review 10.  Topoisomerase inhibitors. A review of their therapeutic potential in cancer.

Authors:  B K Sinha
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.